For the three months ended September 30, 2022, we had a net income of $1,185,063, which included a gain from the change in fair value of warrant liabilities of $326,043, a gain from change in fair value of convertible note of $28,992 and interest income of $1,045,565, partially offset by a loss from operations of $215,537.
For the nine months ended September 30, 2022, we had a net income of $6,665,853, which included a gain from the change in fair value of warrant liabilities of $6,134,219, a gain from change in fair value of convertible note of $29,350 and interest income of $1,372,427, partially offset by a loss from operations of $870,143.
For the three months period ended September 30, 2021, we had net income of $834,468, which consisted of $363,710 in formation and operating costs offset by $2,959 in interest earned on investments held in the Trust Account and a gain from the change in fair value of warrant liability of $1,195,219.
For the period from January 21, 2021 (inception) through September 30, 2021, we had net income of $5,033,559, which consisted of $889,857 in formation and operating costs and $548,600 of expenses related to the IPO, offset by $5,970 in interest earned on marketable securities held in the Trust Account and a gain from the change in fair value of warrant liability of $6,466,046.
Liquidity, Capital Resources and Going Concern
On May 6, 2021 we consummated our IPO and Private Placement and on May 11, 2021 the underwriters fully exercised their over-allotment option and substantially concurrently therewith, we completed the private sale of an aggregate of 400,000 additional Private Placement Warrants. Of the net proceeds from the IPO, exercise of the over-allotment option, and associated Private Placements, $230,000,000 of cash was placed in the Trust Account and $1,961,865 of cash was held outside of the Trust Account and is available for working capital purposes. Until the consummation of the IPO, our only source of liquidity was an initial purchase of ordinary shares by the Sponsor and loans from the Sponsor and a related party.
Our initial shareholders, officers, directors or their affiliates may, but are not obligated to, loan us funds as may be required (“Working Capital Loans”). If we complete a Business Combination, we may repay the Working Capital Loans out of the proceeds of the Trust Account released to us. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, we may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans, other than the interest on such proceeds that may be released for working capital purposes. Our amended and restated memorandum and articles of association provide that we will have only until May 6, 2023 to complete our initial business combination. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into Private Placement Warrants of the post Business Combination entity at a price of $1.50 per warrant. As of September 30, 2022, no Working Capital Loans were outstanding.
On February 28, 2022, we entered into a convertible note with the Sponsor, pursuant to which the Sponsor agreed to loan us up to an aggregate principal amount of $300,000 (the “Convertible Note”). The Convertible Note is non-interest bearing and due on the earlier of: (i) 12 months from the date thereof or (ii) the date on which we consummate a business combination. If we do not consummate a business combination, we may use a portion of any funds held outside the Trust Account to repay the Convertible Note; however, no proceeds from the Trust Account may be used for such repayment if we do not consummate the Business Combination. Up to $300,000 of the Convertible Note may be converted into warrants at a price of $1.50 per warrant at the option of the Sponsor. The warrants would be identical to the Private Placement Warrants.
At September 30, 2022, we had cash and cash equivalents outside the Trust Account of $200,042 and working capital of $22,277. Over the next 12 months, we will be using these funds for paying existing accounts payable, identifying and evaluating prospective Initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination. These conditions raise substantial doubt about our ability to continue as a going concern. Management plans to address this with the consummation of a proposed Business Combination in the combination period or with Working Capital Loans. Our Sponsor is committed and prepared to loan additional working capital to fund operations. There is no assurance that our plans to consummate a proposed business combination will occur or we will be able to borrow needed capital. As such, there is substantial doubt about our ability to continue as a going concern.
24